Related Experiment Video

Updated: Jul 12, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K

Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer

Lorenz Frehner1, Simon Haefliger1, Ferdinando Cerciello1

  • 1Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Case Reports in Oncology
|October 30, 2023
PubMed

Insights

Larotrectinib shows efficacy in neurotrophic receptor kinase (NTRK) gene 2-positive non-small cell lung cancer (NSCLC). This case study suggests TRK inhibitors may benefit patients with NTRK2 fusions, expanding treatment options for NSCLC.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) treatment can involve targeting neurotrophic receptor kinase (NTRK) gene fusions.
  • Tropomyosin kinase (TRK) inhibitors are effective for NSCLC with NTRK1 or NTRK3 fusions.
  • Efficacy data for TRK inhibitors in NSCLC with NTRK2 fusions were previously unavailable.

Observation:

  • A case report details a female patient diagnosed with NSCLC.
  • The patient's tumor harbored an NTRK2 gene fusion.
  • The patient received larotrectinib, a TRK inhibitor.

Findings:

  • The patient achieved a complete and ongoing response to larotrectinib therapy.
  • This response suggests larotrectinib is effective in NSCLC with an NTRK2 fusion.

Implications:

  • First-generation TRK inhibitors may be effective for NSCLC patients with NTRK2 fusions.
  • These findings could expand the use of TRK inhibitors in a broader NSCLC population.
  • Further research is warranted to confirm the efficacy of TRK inhibitors in NTRK2-positive NSCLC.
Keywords:
NTRK2Non-small cell lung cancerTargeted therapy

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K